{
    "clinical_study": {
        "@rank": "26787", 
        "acronym": "TULIP", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Placebo Comparator", 
                "description": "TA-8995 0mg (placebo) & placebo statin"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "TA-8995 1mg & placebo statin"
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Experimental", 
                "description": "TA-8995 2.5mg & placebo statin"
            }, 
            {
                "arm_group_label": "Group 4", 
                "arm_group_type": "Experimental", 
                "description": "TA-8995 5mg & placebo statin"
            }, 
            {
                "arm_group_label": "Group 5", 
                "arm_group_type": "Experimental", 
                "description": "TA-8995 10mg & placebo statin"
            }, 
            {
                "arm_group_label": "Group 6", 
                "arm_group_type": "Active Comparator", 
                "description": "TA-8995 0mg (placebo) & atorvastatin 20mg"
            }, 
            {
                "arm_group_label": "Group 7", 
                "arm_group_type": "Active Comparator", 
                "description": "TA-8995 10mg & atorvastatin 20mg"
            }, 
            {
                "arm_group_label": "Group 8", 
                "arm_group_type": "Active Comparator", 
                "description": "TA-8995 0mg (placebo) & rosuvastatin 10mg"
            }, 
            {
                "arm_group_label": "Group 9", 
                "arm_group_type": "Active Comparator", 
                "description": "TA-8995 10mg & rosuvastatin 10mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the efficacy of different doses of\n      TA-8995, a cholesteryl ester transfer protein (CETP) inhibitor, on the elevation of\n      high-density lipoprotein cholesterol (HDL-C) and reduction of low-density lipoprotein\n      cholesterol (LDL-C), alone and in combination with statin therapy.\n\n      The secondary objectives of this study are to determine the safety and tolerability of\n      TA-8995 in patients with mild dyslipidaemia."
        }, 
        "brief_title": "TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)", 
        "condition": "Dyslipidemia", 
        "condition_browse": {
            "mesh_term": "Dyslipidemias"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Fasting LDL-C levels >2.5 mmol/L and <4.5 mmol/L, HDL-C levels <1.8 mmol/L and >0.8\n             mmol/L, and TG levels <4.5 mmol/L after run in or washout of existing therapies\n\n          -  Not on lipid-altering therapy at screening or on lipid-altering treatment regimens at\n             screening\n\n        Exclusion Criteria:\n\n          -  Body mass index >32 kg/m2;\n\n          -  Participation in another clinical study involving an investigational or marketed drug\n             within 30 days prior to enrolment (Visit 2);\n\n          -  Any clinical manifestation of atherosclerotic vascular disease;\n\n          -  Diagnosis of type 1 diabetes;\n\n          -  Uncontrolled type 2 diabetes: haemoglobin A1c >8%;\n\n          -  Uncontrolled hypertension: sitting systolic blood pressure >160 mmHg and/or sitting\n             diastolic blood pressure >90 mmHg;\n\n          -  History of hyperaldosteronism;\n\n          -  Active muscle disease or persistent creatine kinase concentration >3 \u00d7 the upper\n             limit of normal (ULN). One retest will be allowed after 1 week to verify the result;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "378", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01970215", 
            "org_study_id": "TA-8995-03", 
            "secondary_id": "2012-005643-24"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group 2", 
                    "Group 3", 
                    "Group 4", 
                    "Group 5", 
                    "Group 7", 
                    "Group 9"
                ], 
                "intervention_name": "TA-8995", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group 6", 
                    "Group 7"
                ], 
                "intervention_name": "Atorvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group 8", 
                    "Group 9"
                ], 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 6", 
                    "Group 8"
                ], 
                "intervention_name": "TA-8995 0mg (placebo)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2", 
                    "Group 3", 
                    "Group 4", 
                    "Group 5"
                ], 
                "intervention_name": "Placebo Statin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Atorvastatin", 
                "Hydroxymethylglutaryl-CoA Reductase Inhibitors", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark"
                    }, 
                    "name": "H:S Amager Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Esbjerg", 
                        "country": "Denmark"
                    }, 
                    "name": "Sydvestjysk Sygehus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Herlev", 
                        "country": "Denmark"
                    }, 
                    "name": "Herlev University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hvidovre", 
                        "country": "Denmark"
                    }, 
                    "name": "Hvidovre Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Silkeborg", 
                        "country": "Denmark"
                    }, 
                    "name": "Regionshopitalet - Silkeborg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Almere", 
                        "country": "Netherlands"
                    }, 
                    "name": "EB FlevoResearch B.V"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Andromed Leiden"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Andromed Amsterdam"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam-Zuidoost", 
                        "country": "Netherlands"
                    }, 
                    "name": "Academic Medical Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Breda", 
                        "country": "Netherlands"
                    }, 
                    "name": "Andromed Breda B.V"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Eindhoven", 
                        "country": "Netherlands"
                    }, 
                    "name": "Andromed Eindhoven"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands"
                    }, 
                    "name": "Andromed Noord B.V"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leiderdorp", 
                        "country": "Netherlands"
                    }, 
                    "name": "Andromed Zoetermeer"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Andromed Rotterdam BV"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sliedrecht", 
                        "country": "Netherlands"
                    }, 
                    "name": "Albert Schweitzer Ziekenhuis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Velp", 
                        "country": "Netherlands"
                    }, 
                    "name": "Andromed Oost"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zwijndrecht", 
                        "country": "Netherlands"
                    }, 
                    "name": "Praktijk Zwijndrecht"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Denmark", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "9", 
        "official_title": "A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of TA-8995 in Patients With Mild Dyslipidaemia, Alone and In Combination With Statin Therapy", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark : Danish Medicines and Health Authority", 
                "The Netherlands : Healthcare Inspectorate"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The co-primary efficacy endpoints are the percentage changes in both HDL-C and LDL-C levels at Week 12 compared to baseline.", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01970215"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Xention Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xention Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}